INVESTIGATION OF GLYCOPROTEIN, FIBER AND GROWTH FACTOR EXPRESSIONS IN PATIENTS WITH PLACENTA PREVIA, PLACENTA PERFORATA IN THE 3RD TRIMESTER OF PREGNANCY

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Placenta previa can cause a risk of severe bleeding during labor. Placenta previa is usually classified into four different types: total, partial, marginal and asymptomatic. The condition is diagnosed by ultrasonography later in pregnancy and its management varies depending on the location of the placenta and the presence of bleeding. Studies show that the increased frequency of placenta previa is associated with increased cesarean section rates and maternal age (1). Furthermore, the effects of placenta previa on maternal and fetal morbidity can be reduced with proper management (2). Placenta percreata is a condition in which the placenta invades the myometrium (uterine muscle) and serosa (outer surface of the uterus). This can make postpartum detachment of the placenta difficult, leading to severe bleeding and complications. Placenta perforata is often associated with placenta previa and may require surgical intervention. Ultrasonography and magnetic resonance imaging (MRI) are used to diagnose this condition. Risk factors include previous cesarean deliveries and placenta previa (3). Placenta percreata requires careful management as it increases the risk of maternal mortality and morbidity (4). In this study, we aimed to investigate the levels of decorin, laminin, collagen-1, TGFβ-1, PDGF in placentas of pregnant women with placenta percreata and previa.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: t
View:

• Healthy pregnancy under 37 weeks

• Age range 18-50

• Being literate in Turkish

• Not having any additional disease

• Agreeing to participate in the study

Locations
Other Locations
Turkey
Manisa Celal Bayar University
RECRUITING
Manisa
Time Frame
Start Date: 2025-02-20
Estimated Completion Date: 2025-11-20
Participants
Target number of participants: 48
Treatments
Group 1: Pregnant women with Placenta Percreata
Group 2: Pregnant women with Placenta Previa
Group 3: Control
Related Therapeutic Areas
Sponsors
Leads: Celal Bayar University

This content was sourced from clinicaltrials.gov